Cardiovascular Outcomes in Type 2 Diabetes Medications

This chapter compares the effectiveness of semaglutide, dulaglutide, and empagliflozin concerning cardiovascular outcomes for type 2 diabetes patients, emphasizing semaglutide's benefits for younger individuals. The discussion also addresses the limitations and economic implications of these treatments, along with the need for future research on related medications and their long-term impacts.